Scarica l'app Stockscreener
2.50
11.11%
0.25
Dopo l'orario di chiusura:
2.60
0.10
+4.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.25
Aprire:
$2.25
Volume 24 ore:
901.78K
Relative Volume:
3.96
Capitalizzazione di mercato:
$69.61M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-0.3877
EPS:
-6.4491
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
+2.88%
1M Prestazione:
-4.21%
6M Prestazione:
-22.36%
1 anno Prestazione:
-50.30%
Intervallo 1D:
$2.23
$2.55
Intervallo di 1 settimana:
$2.22
$2.55
Portata 52W:
$2.22
$5.86
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta VTGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.50 | 69.61M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India
Mental Disorder Treatment Market Innovations and Key Players: - openPR
PD-LID Market Growth to Accelerate in Forecast Period - openPR
VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa
VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com
VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India
Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World
Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com
Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online
Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan
Vistagen to Present at the Stifel 2024 Healthcare Conference - Business Wire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada
Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks
Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire
Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks
Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com
Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire
Vistagen to Present Breakthrough SAD Treatment Data at 2024 NEI Congress - StockTitan
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat
Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise
VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR
Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN
Mental Disorder Treatment Market Global Industry Forecast - openPR
Vistagen, The Goldie Hawn Foundation, and MindUP students Rings the Nasdaq Stock Market Closing Bell on World Mental Health Day - Nasdaq
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance UK
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day - sharewise
Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance
Vistagen advances phase 3 trial for social anxiety treatment By Investing.com - Investing.com Australia
Vistagen advances phase 3 trial for social anxiety treatment - Investing.com
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):